Predicine, Inc. A leading precision oncology company, announced that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.
HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.
The forthcoming data represents significant potential for the practical application of Predicine’s cutting-edge liquid biopsy technology in personalized cancer care, clinical trials and Companion Diagnostic (CDx) advancement.
Numerous studies to be unveiled at the conference emphasize the distinct advantages of personalized PredicineBEACON™ and methylation-based PredicineALERT™ MRD underscoring the clinical utility of Predicine’s complete range of liquid biopsy solutions in biomarker discovery, therapy selection, response monitoring and drug resistance mechanism analyses.
| Predicine Oral Presentation | ||
| Presenter | Title | Product |
| Tuesday, April 9 | 10:45 am – 11:05 am | ||
| Harshabad Singh | Biomarkers for optimal precision therapy in gastroesophageal cancers | PredicineBEACON™ PredicineALERT™ PredicineCARE™ ULTRA |
| Full List of Predicine Presentations | |||
| Abstract | Poster | Title | Product |
| Sunday, April 7 | 1:30 pm – 5:00 pm | |||
| 940 | 8 | Integrated analysis of ctDNA fragmentomics, DNA methylation and cfRNA transcription in metastatic castration-resistant prostate cancer (mCRPC) | PredicineCOMPLETE™ |
| Monday, April 8 | 9:00 am – 12:30 pm | |||
| 2410 | 6 | Comparative Genomic Profiling of Unresectable NSCLC Patients in the U.S. and China Using A Globally Harmonized Liquid Biopsy Approach | PredicineCARE™ |
| 1752 | 7 | Comprehensive genomic profiling of advanced breast cancer subtypes: insights from liquid biopsy analysis and implications for personalized therapies | PredicineCARE™ |
| 2294 | 5 | Monitoring glioma treatment response through longitudinal analysis of cell-free DNA in cerebrospinal fluid: Insights from a comprehensive study using next- generation sequencing | PredicineCARE™ PredicineSCORE™ |
| 2302 | 13 | Innovative blood-based cell-free RNA whole transcriptome sequencing for comprehensive RNA profiling in patient plasma samples and its clinical applications | cfRNA whole trascriptome sequencing (WTS) assay |
| 1738 | 23 | Precise detection of benign and malignant renal tumor via epigenetic characteristics of urinary cell-free DNA | PredicineEPIC™ |
| Monday, April 8 | 1:30 pm – 5:00 pm | |||
| 3663 | 8 | Extending and analytical validation of a hematological cancer panel for simultaneous detection of driver mutations, copy number variations and translocations in tissue and blood samples | PredicineHEME™ |
| 3669 | 14 | Clinical applications of urinary DNA methylation biomarkers for identifying patients with non- muscle invasive bladder cancer | PredicineEPIC™ PredicineBEACON™ |
| 3505 | 27 | Classification of cancer subtypes by cfDNA fragmentomics analysis | PredicineSCORE™ |
| 3479 | 1 | Evaluation of Subclonal Deconvolution Pipelines Using Reference Cell-lines and Patient Plasma Samples | PredicineWES+™ |
| Tuesday, April 9 | 9:00 am – 12:30 pm | |||
| 5029 | 16 | VAF in ctDNA correlated with advanced breast cancer tumor burden and prognosis | PredicineCARE™ |
| 4878 | 3 | Enhancing Non-Invasive Detection of Urotherlial Carcinoma through Combined Cytology and Methylation Profiling of urinary cell- free DNA | PredicineEPIC™ |
| 5015 | 2 | Genomic Profiling of Colorectal Cancer – Insights from Liquid Biopsy Comparisons between U.S. and China Cohorts | PredicineCARE™ |
| 4950 | 15 | Applying Fragmentomics Profiles of Plasma Cell-free DNA for Breast Cancer Detection | PredicineSCORE™ |
About Predicine
Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology, and infectious disease diagnostics. Predicine is developing proprietary cell-free DNA- and cell-free RNA-based liquid biopsy technologies to enable minimally invasive molecular diagnosis for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring and disease progression. The Predicine portfolio includes blood-, urine-, and tissue-based NGS assays designed for global harmonized use in research, clinical investigation, and CDx development. Through its business operations in Silicon Valley, Houston, Chicago, Los Angeles, Boston, Shanghai, Berlin, Singapore, Beijing, Suzhou, and Harbin. Predicine is partnering and collaborating with leading biopharma companies, institutions, and governments to support personalized healthcare on a global scale. Further information is available on the company’s website, http://www.predicine.com. Stay in touch on LinkedIn or @Predicine on Twitter. Reach out to us at media@predicine.com.
Contact Information:
Predicine, Inc.
media@predicine.com
